Eradication of Methicillin-Resistant Staphylococcus aureus in Cystic Fibrosis.

IF 0.7 4区医学 Q3 PEDIATRICS

Clinical Pediatrics Pub Date : 2025-10-01 DOI:10.1177/00099228251375413

Aynur Guliyeva, Cansu Yilmaz Yegit, Muruvvet Yanaz, Mine Kalyoncu, Merve Selçuk Balci, Seyda Karabulut, Gamze Tastan, Burcu Uzunoglu, Hüseyin Arslan, Hakan Yazan, Gülay Bas Bilgin, Ayse Ayzıt Kılınc Sakallı, Almala Pinar Ergenekon, Saniye Girit, Erkan Cakır, Yasemin Gokdemir, Ela Erdem Eralp, Fazilet Karakoc, Bulent Karadag

{"title":"Eradication of Methicillin-Resistant Staphylococcus aureus in Cystic Fibrosis.","authors":"Aynur Guliyeva, Cansu Yilmaz Yegit, Muruvvet Yanaz, Mine Kalyoncu, Merve Selçuk Balci, Seyda Karabulut, Gamze Tastan, Burcu Uzunoglu, Hüseyin Arslan, Hakan Yazan, Gülay Bas Bilgin, Ayse Ayzıt Kılınc Sakallı, Almala Pinar Ergenekon, Saniye Girit, Erkan Cakır, Yasemin Gokdemir, Ela Erdem Eralp, Fazilet Karakoc, Bulent Karadag","doi":"10.1177/00099228251375413","DOIUrl":null,"url":null,"abstract":"Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) in cystic fibrosis (CF) impairs lung function and contributes to the progression of the disease. Optimal eradication regimens for new-onset MRSA infections in people with CF (pwCF) remain undefined.Materials and methods: This prospective, multicenter study evaluated a standardized, step-up MRSA eradication regimen in pwCF with new-onset MRSA infections between 2020 and 2022.Results: Ninety-one pwCF (52.7% male, median age: 9 years) were included. Our treatment regimen included oral rifampicin and co-trimoxazole or oral rifampicin and fusidic acid. Intravenous teicoplanin treatment was initiated in patients whose clinical condition was unstable. The eradication success rates after 1 year were 82.4%, 92.9%, and 55.6%, respectively. No significant changes in median FEV1% predicted or BMI z-scores were observed between MRSA-eradicated and non-eradicated groups at baseline or 12 months.Conclusion: A standardized step-up MRSA eradication protocol is effective for new-onset MRSA infections in pwCF. Randomized controlled trials are needed to confirm these findings.","PeriodicalId":10363,"journal":{"name":"Clinical Pediatrics","volume":" ","pages":"99228251375413"},"PeriodicalIF":0.7000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/00099228251375413","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) in cystic fibrosis (CF) impairs lung function and contributes to the progression of the disease. Optimal eradication regimens for new-onset MRSA infections in people with CF (pwCF) remain undefined.

Materials and methods: This prospective, multicenter study evaluated a standardized, step-up MRSA eradication regimen in pwCF with new-onset MRSA infections between 2020 and 2022.

Results: Ninety-one pwCF (52.7% male, median age: 9 years) were included. Our treatment regimen included oral rifampicin and co-trimoxazole or oral rifampicin and fusidic acid. Intravenous teicoplanin treatment was initiated in patients whose clinical condition was unstable. The eradication success rates after 1 year were 82.4%, 92.9%, and 55.6%, respectively. No significant changes in median FEV1% predicted or BMI z-scores were observed between MRSA-eradicated and non-eradicated groups at baseline or 12 months.

Conclusion: A standardized step-up MRSA eradication protocol is effective for new-onset MRSA infections in pwCF. Randomized controlled trials are needed to confirm these findings.

查看原文本刊更多论文

囊性纤维化中耐甲氧西林金黄色葡萄球菌的根除。

导言：囊性纤维化（CF）中耐甲氧西林金黄色葡萄球菌（MRSA）损害肺功能并促进疾病进展。CF （pwCF）患者新发MRSA感染的最佳根除方案仍未确定。材料和方法：这项前瞻性、多中心研究评估了2020年至2022年间新发MRSA感染的pwCF患者的标准化、逐步根除MRSA方案。结果：纳入91例pwCF患者（52.7%为男性，中位年龄9岁）。我们的治疗方案包括口服利福平和复方新诺明或口服利福平和夫西地酸。临床情况不稳定的患者开始静脉注射替柯planin治疗。1年后根除成功率分别为82.4%、92.9%和55.6%。在基线或12个月时，mrsa根除组和未根除组的预测fev1的中位数或BMI z评分没有显著变化。结论：标准化的强化MRSA根除方案对pwCF新发MRSA感染有效。需要随机对照试验来证实这些发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Pediatrics 医学-小儿科

CiteScore

2.10

自引率

6.20%

发文量

189

审稿时长

3-8 weeks

期刊介绍： Clinical Pediatrics (CLP) a peer-reviewed monthly journal, is a must read for the busy pediatrician. CLP contains state-of-the-art, accurate, concise and down-to earth information on practical, everyday child care topics whether they are clinical, scientific, behavioral, educational, or ethical.